FDA requires GLP-1 weight-loss drugs to warn of rare eye condition

· Science · United States

The US Food and Drug Administration is requiring makers of Ozempic, Wegovy and similar drugs to warn of a rare eye condition that can cause vision loss, Medical Xpress reports. The labeling change covers the GLP-1 class of medicines, which are used for diabetes and weight loss. The item does not name the condition, the companies affected, the evidence behind the requirement, or how frequently the side effect has been reported. GLP-1 drugs have become among the most widely prescribed medicines, with prescribing expanding rapidly. A new class-wide warning means manufacturers must revise labels, and prescribers and patients will be alerted to a rare but potentially serious risk, adding a consideration to treatment decisions that have so far been driven mainly by benefits.

Why it matters：A class-wide warning adds a safety consideration to some of the world's most widely prescribed drugs, affecting labelling, prescribing behaviour and pharmacovigilance for GLP-1 makers.

Key points

  • The FDA requirement covers Ozempic, Wegovy and similar drugs.
  • The warning concerns a rare condition that can cause vision loss.
  • Neither the condition nor affected manufacturers were named in the item.

Sources (original reporting)

More stories from this day